Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 in primary membranous nephropathy
NCT05398653Phase 2Completed
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Feb 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Bejescin in primary membranous nephropathy (PMN), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Started Feb 2022; status: completed.
02
Drugs
Bejescin
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05398653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398653.